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SUMMARY
A comparison of the Etest and the reference broth macrodilution susceptibility test for fluconazole, ketoconazole, itraconazole
and amphotericin B was performed with 59 of Candida species isolated from the oral cavities of AIDS patients. The Etest method was
performed according to the manufacturer´s instructions, and the reference method was performed according to National Committee
for Clinical Laboratory Standards document M27-A guidelines. Our data showed that there was a good correlation between the MICs
obtained by the Etest and broth dilution methods. When only the MIC results at ± 2 dilutions for both methods were considered, the
agreement rates were 90.4% for itraconazole, ketoconazole and amphotericin B and 84.6% for fluconazole of the C. albicans tested.
In contrast, to the reference method, the Etest method classified as susceptible three fluconazole-resistant isolates and one itraconazole-
resistant isolate, representing four very major errors. These results indicate that Etest could be considered useful for antifungal
sensitivity evaluation of yeasts in clinical laboratories.
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INTRODUCTION
Unlike antibacterial assays, standardized methods for testing
antifungal agents are not generally available in most microbiological
laboratories. Owing to the increased fungal infection rates in
immunocompromised patients, including those with AIDS and recipients
of solid organ transplants and cytotoxic chemotherapy, have created new
challenges in the area of antimicrobial drug therapy, much effort has
been undertaken to obtain a standardized rapid and reliable routine
method for in vitro susceptibility testing of antifungal substances5,6,9,16.
So, the publication in 1992 by the National Committee for Clinical
Laboratory Standards (NCCLS)10 of the proposed broth macrodilution
reference for yeast, NCCLS M27-P document, which was moved to the
tentative level, or M27-T, in 199511 and the NCCLS M-27 A in 199712,
documents are an important landmark in the field of testing antifungal
susceptibilities. This method provides guidelines for testing the antifungal
susceptibilities of Candida spp and Cryptococcus neoformans and shows
interpretative breakpoints in susceptible, dose dependent and resistant
for Candida species against itraconazole, fluconazole and flucytosine
(NCCLS, 1997)12.
The Etest (AB Biodisk, Solna, Sweden) is now well established as
an excellent method for in vitro testing of antimicrobial agents against
numerous microbial pathogens and the adaptation to in vitro susceptibility
testing of fungi has also met with reasonable success1,2,8,18,20. This method
is based on the diffusion of a continuous concentration gradient of the
antifungal agent tested from a plastic strip into an agar medium. Since
these strips contain a predefined continuous grade of a drug, it is possible
to obtain reproducible quantitative MIC readings13,18.
In the present study, we compared a broth macrodilution assay,
performed in accordance with NCCLS guidelines, and Etest method by
determining the MICs of four antifungal agents for 59 clinical isolates
of yeasts pathogenic isolated from patients with AIDS.
MATERIALS AND METHODS
Organisms: Fungal isolates were obtained from 86 swabs of the
oral mucosa from AIDS patients during the initial diagnosis of candidiasis
infections who were attended in the Hospital de Doenças Tropicais de
Goiânia (HDT) from January to December 2000. Swabs were streaked
for isolation onto Sabouraud dextrose agar (SDA) and the yeasts isolated
were identified by standard methods7. Fifty nine isolates belonged to
the genus Candida; of these 88.1% (52/59) were identified as C. albicans,
6.7% (4/59) as C. tropicalis and 5% (3/59) as C. krusei. Each isolated
was stored at ambient temperature until testing was performed, when
were subcultured on SDA for 18-24 hours at 35 oC to ensure their purity
and viability. These isolates were selected for susceptibility testing.
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The test organism included American Type Culture Collection C.
albicans (ATCC 10231) used as control in susceptibility tests.
All the isolates were tested by reference broth macrodilution method
and by the Etest. The antifungal agents evaluated were amphotericin B
(E.R. Squibb & Sons), ketoconazole and itraconazole (Janssen
Pharmaceuticals) and fluconazole (Pfizer, Inc., New York, N.Y). All the
tests were run in duplicate.
Broth macrodilution method: The broth macrodilution method was
performed by following the guidelines in NCCLS document M27-A12.
It was performed in RPMI 1640 supplemented with 0.3 g of glutamine/
L, buffered with 34.6 g morpholinepropanesulfonic acid (MOPS) and
adjusted pH 7.0, contained 2 g of glucose. Fluconazole, ketoconazole,
itraconazole and amphotericin B were obtained as reagent-grade powders
from their respective manufacturers. Amphotericin B, ketoconazole and
itraconazole were dissolved in dimethyl sulfoxide at a concentration of
320 g/mL, and fluconazole was dissolved in 0.85% saline at a
concentration of 2560 g/mL. Stock solution were stored at –70 oC until
used. The stock yeast inoculum suspensions were adjusted to 1X 106 to
5X 106 CFU/mL by the spectrophotometric method. Briefly, an inoculum
suspension was prepared for each isolate from 24 hours old cultures
grown at 35 ºC and the turbidities of the resulting yeast suspension were
measured with spectrophotometer at 530 nm and were adjusted to the
percent transmission that matched a 0.5 Mc Farland standard. The
working suspension was made by a 1:100 dilution followed by a 1:20
dilution in RPMI 1640 broth medium in sufficient volume to directly
inoculate each MIC tube with 0.9 mL. Yeast inocula (0.9 mL) were added
to each tube containing 0.1 mL antifungal drug solution. The range final
concentration was from 0.002 to 32 g/mL for amphotericin B,
ketoconazole and itraconazole and 0.016 to 256 g/mL to fluconazol.
The tubes were incubated at 35 oC and were inspected after 48 hours of
incubation. Drug-free and yeast-free controls were included. For the
azoles, itraconazole, ketoconazole and fluconazole, the MIC was
established as the lowest antifungal concentration that inhibited 80% of
the control growth (0.2 mL of growth control plus 0.8 mL of uninoculated
RPMI). For amphotericin B, endpoints were determined visually by
recording the lowest concentration of the agent that prevented the
appearance of visible growth3,12.
Agar diffusion Etest: The Etest antifungal gradient strips were
provided by the manufacturer (AB BIODISK, Solna, Sweden). RPMI
agar for the agar diffusion Etest was prepared the same way as the RPMI
broth and supplemented with 18 g of glucose/L and 15 g of Bacto agar/
L. The concentration gradient for itraconazole, ketoconazole and
amphotericin B ranged from 0.002 to 32 g/mL and the fluconazole
ranged from 0.016 to 256 g/mL. The strips were stored at –20 oC until
use. Each solidified medium was inoculated by dipping a sterile swab
into the cell suspension (5X 105 cells/mL) and streaking it across in the
surface of the agar in three directions. The plates were allowed to dry for
at least 15 min before the Etest strip was applied to the surface. The
plates were incubated at 35 oC and MICs were determined following
incubation time of 24 h. Determination of MIC endpoints by the Etest
was the lowest drug concentration at which the border of the elliptical
inhibition zone intercepted the scale on the antifungal strip.
Analysis of results: A total of 960 MICs for ATCC isolates and the
59 clinical yeast isolates were obtained and analyzed. Both on-scale and
off-scale results were included in the analysis. The high off-scale MIC
(>32 and >256 g/mL) were converted to the next highest (64 and 512
g/mL) concentration and the low off-scale (MICs < 0.002 and < 0.016
g/mL) were left unchanged. Discrepancies among MIC endpoints of
no more than 2 dilutions were used to calculate the percent agreement.
According to the NCCLS12 criteria, isolates for fluconazole which
MICs are  8 g/mL are classified as susceptible, while those for which
MICs are  64 g/mL are classified as resistant and isolates for which
MICs are 16 to 32 g/mL are termed susceptible dose dependent (S-
DD). Isolates for which itraconazole MICs are  0.125 g/mL are
classified as susceptible, while those for which MICs are 0.25 to 0.5 g/mL
are classified as S-DD, and those for which MICs are  1 g/mL are
classified as resistant.
To permit comparison between the results of the two methods, the
NCCLS breakpoints were applied to both tests for these agents. Major
errors were defined as results in which the reference method result was
susceptible and the Etest method result was resistant, while very major
errors were defined as results in which the reference method result was
resistant and the Etest method result was susceptible. Minor errors were
defined as variations in results from resistant to S-DD or S-DD to
susceptible between the two methods6.
RESULTS
Table 1 summarizes the in vitro susceptibility (MICs) of 52 C.
albicans; 04 C. tropicalis; 03 C. krusei isolates for itraconazole,
fluconazole, ketoconazole and amphotericin B by the two methods. The
data are reported as the concentrations of antifungals agents necessary
to inhibit 50% (MIC50) and 90% (MIC90) of the isolates tested.
Itraconazole, ketoconazole and fluconazole MICs showed a broad range
for all the species. Amphotericin B MICs showed a very narrow range
for the species tested.
Agreement between the macrodilution method and the Etest method
was good for all antifungal agents toward C. albicans. In contrast, the
agreement among the methods was lowest for itraconazole toward C.
krusei (66.7%) and fluconazole, ketoconazole and amphotericin B toward
C. tropicalis (75%). With regard to fluconazole, the Etest often produced
inhibition zones with difuses edges. For 25% of the C. tropicalis isolates
growth of microcolonies with decreasing intensity just inside the border
of the inhibition zone was observed. The percent of agreement between
the broth macrodilution and Etest methods of the 59 isolates to
amphotericin B, fluconazole, ketoconazole and itraconazole is showed
in table 1. A complete agreement of Etest MIC with reference broth
macrodilution method MIC was verified when the four antifungal agents
were tested against C. albicans ATCC 10231.
The itraconazole and fluconazole susceptibility data are reported in
Table 2. This table shows the number of isolates (for each specie)
classified as susceptible (S), susceptible dose dependent (S-DD), and
resistant (R) based on the results of the two methods tested.
Table 3 details the susceptibility interpretation discrepancies between
the two methods for the two drugs with NCCLS- defined breakpoints
(fluconazole and itraconazole). Very major errors, in which the reference
method classified an isolate as resistant and the Etest method classified
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Table 3
Discrepancies between test method for antifungal agents with NCCLS-defined MIC breakpoints for all organisms tested
No. of discrepant resultsa
Organisms/ Minorb Majorc Very majord
antifungal agents S vs S-DDe S-DD vs S S-DD vs R R vs S-DD S vs R R vs S
C. albicans (52)
Itraconazole 3 2 0 0 0 0
Fluconazole  0 1 0 0 0 3
C. tropicalis (04)
Itraconazole 0 1 0 0 0 0
Fluconazole 0 0 0 0 0 0
C. krusei (03)
Itraconazole 0 0 0 0 0 1
Fluconazole 0 0 0 0 0 0
a S, susceptible; S-DD, Susceptible-dose dependent; R, resistant; b Minor difference between method were those which changed the susceptibility category from
susceptible to S-DD, S-DD to susceptible, S-DD to resistant, or resistant to S-DD; c Major differences were those in which the reference method classified isolates
as susceptible and the Etest method classified isolates as resistant; d Very major differences were those in which the reference method classified isolates as resistant
and the Etest method classified isolates as susceptible; e Susceptibility results by the NCCLS method versus those by the Etest method
Table 2
Itraconazole and Fluconazole susceptibility test results obtained with each of the two methods
Antifungals agents/methods
Species Classified as Itraconazole Fluconazole
Macrodilution Etest Macrodilution Etest
S 37 36 42 46
C. albicans (n = 52) S-DD 10 11 1 0
R 5 5 9 6
S 2 3 2 2
C. tropicalis (n = 04) S-DD 2 1 0 0
R 0 0 2 2
S 1 2 NAa NA
C. krusei (n = 03) S-DD 0 0 NA NA
R 2 1 NA NA
aNA, not applicable - Reference MIC breakpoints have not been applied to C. krusei.
Table 1
Antifungal susceptibilities of 59 clinical isolates of yeasts: MIC results, agreement rate between Etest and NCCLS methods
Broth macrodilution (g/mL) Etest (g/mL) %
Organism Antifungals Range MIC50 MIC90 range MIC50 MIC90 agreement
C. albicans Itraconazole 0.002->32 0.064 0.50 0.002->32 0.094 0.50 90.4
n = 52 Ketoconazole 0.064->32 0.25 >32 0.064->32 0.25 >32 90.4
Fluconazole 0.19->256 4.0 >256 0.016->256 3.0 >256 84.6
Amphotericin B 0.125-2.0 0.50 1.50 0.094-3.0 1.0 1.50 90.4
C. tropicalis Itraconazole 0.016-0.38 0.064 0.38 0.032-0.38 0.064 0.38 100
n = 04 Ketoconazole 0.25->32 1.0 >32 0.125->32 0.38 >32 75
Fluconazole 0.125->256 1.0 >256 0.25->256 3.0 >256 75
Amphotericin B 0.032-0.50 0.50 0.50 0.064-1.50 1.0 1.50 75
C. krusei Itraconazole 0.064->32 1.50 >32 0.047->32 0.064 >32 66.7
n = 03 Ketoconazole 0.125->32 >32 >32 0.125->32 >32 >32 100
Fluconazole 4.0->256 >256 >256 4.0->256 >256 >256 100
Amphotericin B 0.25-0.75 0.50 0.75 0.25-1.0 0.50 1.0 100
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it as susceptible occurred for fluconazole with three C.albicans isolates
and for itraconazole with one C. krusei isolate. The greatest percentage
of minor errors was noted for itraconazole (six of the seven instances)
and the one error was observed for fluconazole against C. albicans.
Overall, the results indicated that there were only 04 (3.4%) very major
errors and 07 (5.9 %) minor errors between methods for all organisms
tested against fluconazole and itraconazole.
DISCUSSION
Although the NCCLS broth macrodilution methods (M27-A
document)12 improved the level of interlaboratory agreement of antifungal
MIC endpoint, these procedures are not convenient and efficient testing
tools for the clinical laboratory. Several tests that are alternatives to the
NCCLS methodology has been developed and evaluated. Among them,
the Etest is the commercial method that has been investigated for the
testing of pathogenic yeasts. The Etest method has the advantage of
being simple and easy for use1,19. However literature’s data comparing
MICs obtained by Etest with those obtained by macrodilution or
microdilution have shown variable results depending of the antifungal
agent and the species tested, as well as on the medium used for testing1,3,19.
RPMI 1640 medium with 2% glucose used in our study is the medium
recommended for use in the susceptibility testing of yeasts and indicates
that medium improves the reprodutibility of the MICs as determined by
the Etest3,17. Previous comparison by independent laboratories between
Etest and broth macrodilution methods, have showed good agreement
rates for the azoles and flucytosine, when is used the RPMI 16403,24.
In this study we compared the MICs of fluconazole, itraconazole,
ketoconazole and amphotericin B by Etest and broth macrodilution
techniques against 59 isolates of Candida obtained from patients with
AIDS during the initial diagnosis of candidiasis infection. In general,
our data showed that there was a good correlation between the MICs
obtained by the Etest and broth dilution methods, verifying that both
methods showed high MICs values for fluconazole and ketoconazole in
Candida isolates. The highest MICs were observed to fluconazole, mainly
for C. krusei with MIC50 and MIC90 > 32 g/mL. This specie is considered
inherently resistant to fluconazole15. Our results are in accordance with
others that showed high MIC values for azoles in patients with AIDS22.
The strains of Candida are generally sensitive to ketoconazole and
itraconazole23, however in our study MIC90 of ketoconazole for all the
species tested were > 32 g/mL and for itraconazole MIC90 was > 32 µg/
mL for C. krusei. These characteristics can bee explained by the
phenomenon of cross-resistance observed among the family of azole
compound4. Besides, the selection of resistant isolates to azoles would
be explained by the long term of azoles in the prophylaxis therapy for
patients with AIDS23. When the MIC results at ± 2 dilutions for both
methods were considered, the agreement rates were 90.4% for
itraconazole, ketoconazole and amphotericin B and 84.6% for fluconazole
of the C. albicans tested. However, higher discrepancies were noted for
C. krusei and C. tropicalis (Table 1). The determination of the endpoints
because the usual partial growth inhibition (trailing) observed with azoles
was difficult, representing a significant factor in the variability of MIC
results for these drugs. As expected, this was a problem with significant
number of isolates. The growth of microcolonies inside all of the
inhibition zone around the Etest strips was judged in this study to be the
most difficult reading pattern.
It is well known that with exception of fluconazole, itraconazole
and flucytosine breakpoint concentration have not been defined for other
antifungals by the NCCLS. In adition, for fluconazole, these interpretative
breakpoints are not aplicable to C. krusei, because this specie is assumed
to be intrinsically resistant to fluconazole. An analysis of the discrepancies
between test methods for fluconazole and itraconazole with NCCLS
defined MIC breakpoints showed that the greatest number of very major
errors occurred with C. albicans isolates tested against fluconazole and
with C. krusei for itraconazole. These discrepancies in MIC results
between the two methods were likely due to the difficulties of consistently
reading visual MIC endpoints for isolates which produce trailing growth
in the presence of azole antifungal agents. Recently, ST-GERMAIN21
emphasized that trailing growth occur mainly with C. albicans and C.
tropicalis. POSTERARO et al.14 related that the Etest failed to provide
conclusive data on the fluconazole susceptibility of certain isolates of C.
parapsilosis .
 In summary, we obtained a good agreement between the Etest and
the broth dilution methods for the drugs susceptibility testing of Candida
when endpoints determinations were recorded after 24 hours of
incubation for the Etest and 48 hours of incubation for the broth
macrodilution.
In conclusion, considering the high concordance of the results of
both test systems, Etest could be considered useful for antifungal sensivity
evaluation of yeasts in clinical laboratories.
RESUMO
Avaliação dos métodos de suscetibilidade antifúngica: Etest e
macrodiluição em caldo para leveduras do gênero Candida
isoladas da cavidade bucal de pacientes com AIDS
Foram comparados dois testes de suscetibilidade in vitro, macrodiluição
em caldo e Etest através da determinação das concentrações inibitórias
mínimas de fluconazol, cetoconazol, itraconazol e anfotericina B para 59
isolados de Candida obtidos da cavidade bucal de pacientes com AIDS. O
método de Etest foi feito de acordo com as instruções do fabricante e o
método de macrodiluição em caldo foi realizado seguindo as normas do
NCCLS (National Committee for Clinical Laboratoratory Standards),
documento M27-A, considerado método de referência. Nossos dados
mostraram uma boa correlação entre os valores de concentração inibitória
mínima encontrados para o Etest e o método de macrodiluição em caldo.
Foi verificada concordância entre os resultados de CIM, de 90,4% para
itraconazol, cetoconazol e anfotericina B e de 84,6% para fluconazol,
quando se analisou isolados de C. albicans. A comparação de breakpoints
mostrou que havia quatro grandes discrepâncias de resultados entre os
dois métodos, sendo que pelo método de referência três isolados de Candida
albicans classificados como resistentes ao fluconazol e um de C. krusei
considerado resistente ao itraconazol foram sensíveis ao Etest. Estes
resultados mostraram que o Etest é de grande valor nos testes de
suscetibilidade antifúngica para leveduras do gênero Candida.
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